Richa Aishwarya

Richa Aishwarya

Auto-generated profile, based on publicly available information

Richa Aishwarya

Department of Pathology and Translational Pathobiology, LSU Health Shreveport, Shreveport, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2021 in Mitochondrion
Verified
Journal Article
Open access
CAChowdhury S. Abdullah
Chowdhury S. Abdullah
RARicha Aishwarya
Richa Aishwarya
Shafiul AlamShafiul Alam
Shafiul Alam
NRNaznin Sultana Remex
Naznin Sultana Remex
MMMahboob Morshed
Mahboob Morshed
MBMd. Shenuarin Bhuiyan
Md. Shenuarin Bhuiyan
Sigmar1 is a widely expressed molecular chaperone protein in mammalian cell systems. Accumulating research demonstrated the cardioprotective roles of pharmacologic Sigmar1 activation by ligands in preclinical rodent models of cardiac injury. Extensive biochemical and immuno-electron microscopic research demonstrated Sigmar1’s sub-cellular localization largely depends on cell and organ types. Despite comprehensive studies, Sigmar1’s direct molecular role in cardiomyocytes remains elusive. In the present study, we determined Sigmar1’s subcellular localization, transmembrane topology, and function using complementary microscopy, biochemical, and functional assays in cardiomyocytes. Quantum dots in transmission electron microscopy showed Sigmar1 labeled quantum dots on the mitochondrial membranes, lysosomes, and sarcoplasmic reticulum-mitochondrial interface. Subcellular fractionation of heart cell lysates confirmed Sigmar1’s localization in purified mitochondria fraction and lysosome fraction. Immunocytochemistry confirmed Sigmar1 colocalization with mitochondrial proteins in isolated adult mouse cardiomyocytes. Sigmar1’s mitochondrial localization was further confirmed by Sigmar1 colocalization with Mito-Tracker in isolated mouse heart mitochondria. A series of biochemical experiments, including alkaline extraction and proteinase K treatment of purified heart mitochondria, demonstrated Sigmar1 as an integral mitochondrial membrane protein. Sigmar1’s structural requirement for mitochondrial localization was determined by expressing FLAG-tagged Sigmar1 fragments in cells. Full-length Sigmar1 and Sigmar1’s C terminal-deletion fragments were able to localize to the mitochondrial membrane, whereas N- terminal deletion fragment was unable to incorporate into the mitochondria. Finally, functional assays using extracellular flux analyzer and high-resolution respirometry showed Sigmar1 siRNA knockdown significantly altered mitochondrial respiration in cardiomyocytes. Overall, we found that Sigmar1 localizes to mitochondrial membranes and is indispensable for maintaining mitochondrial respiratory homeostasis in cardiomyocytes.

1 January 2022 in The American Journal of Pathology
Verified
Journal Article
Closed access
RARicha Aishwarya
Richa Aishwarya
CAChowdhury S. Abdullah
Chowdhury S. Abdullah
NRNaznin S. Remex
Naznin S. Remex
Shafiul AlamShafiul Alam
Shafiul Alam
MMMahboob Morshed
Mahboob Morshed
MBMd. Shenuarin Bhuiyan
Md. Shenuarin Bhuiyan

26 April 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
NPNilesh Pandey
Nilesh Pandey
HKHarpreet Kaur
Harpreet Kaur
MCMehul R Chorawala
Mehul R Chorawala
SASumit Kumar Anand
Sumit Kumar Anand
LCLakshmi Chandaluri
Lakshmi Chandaluri
NDNirav Dhanesha
Nirav Dhanesha
Venous thromboembolic events are significant contributors to morbidity and mortality in patients with stroke. Neutrophils are among the first cells in the blood to respond to stroke and are known to promote deep vein thrombosis (DVT). Integrin α9 is a transmembrane glycoprotein highly expressed on neutrophils and stabilizes neutrophil adhesion to activated endothelium via vascular cell adhesion molecule 1 (VCAM-1). Nevertheless, the causative role of neutrophil integrin α9 in poststroke DVT remains unknown. Here, we found higher neutrophil integrin α9 and plasma VCAM-1 levels in humans and mice with stroke. Using mice with embolic stroke, we observed enhanced DVT severity in a novel model of poststroke DVT. Neutrophil-specific integrin α9–deficient mice (α9fl/flMrp8Cre+/−) exhibited a significant reduction in poststroke DVT severity along with decreased neutrophils and citrullinated histone H3 in thrombi. Unbiased transcriptomics indicated that α9/VCAM-1 interactions induced pathways related to neutrophil inflammation, exocytosis, NF-κB signaling, and chemotaxis. Mechanistic studies revealed that integrin α9/VCAM-1 interactions mediate neutrophil adhesion at the venous shear rate, promote neutrophil hyperactivation, increase phosphorylation of extracellular signal-regulated kinase, and induce endothelial cell apoptosis. Using pharmacogenomic profiling, virtual screening, and in vitro assays, we identified macitentan as a potent inhibitor of integrin α9/VCAM-1 interactions and neutrophil adhesion to activated endothelial cells. Macitentan reduced DVT severity in control mice with and without stroke, but not in α9fl/flMrp8Cre+/− mice, suggesting that macitentan improves DVT outcomes by inhibiting neutrophil integrin α9. Collectively, we uncovered a previously unrecognized and critical pathway involving the α9/VCAM-1 axis in neutrophil hyperactivation and DVT.

1 July 2022
Verified
Book Chapter
Closed access
PDF file
CAChowdhury S. Abdullah
Chowdhury S. Abdullah
RARicha Aishwarya
Richa Aishwarya
MMMahboob Morshed
Mahboob Morshed
NRNaznin Sultana Remex
Naznin Sultana Remex
SMSumitra Miriyala
Sumitra Miriyala
MBMd. Shenuarin Bhuiyan
Md. Shenuarin Bhuiyan


12 October 2026 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
TITamjid Islam
Tamjid Islam
MSMd Hasif Sinha
Md Hasif Sinha
MMMd Sakil Miah
Md Sakil Miah
PDProma Dhar
Proma Dhar
RARicha Aishwarya
Richa Aishwarya
MBMd. Shenuarin Bhuiyan
Md. Shenuarin Bhuiyan
Doxorubicin (DOX) remains a potent and effective therapy for a broad spectrum of malignancies, including breast cancer, lymphomas, sarcomas, and solid tumo